Evidence map›Paper›PMID 42801624›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Engineered Peptide Self-Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors.

Yubin He, Xiao Lu, Chang Qing Yang, Ran Zhang, Bo Wan, Xin Ni, Dong Mei

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yubin He *Department of Pharmacy, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Xiao Lu *Department of Pharmacy, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Chang Qing YangSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Ran ZhangDepartment of Pharmacy, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Bo WanDepartment of Pharmacy, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0009-0001-8211-0849
Xin NiNational Center for Pediatric Cancer Surveillance, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-7781-2600
Dong MeiDepartment of Pharmacy, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-0801-8702

Funding

Beijing Natural Science Foundation 7232246National Key R&D Program of China 2023YFC2706100National Natural Science Foundation of China 82293660/82293665Sponsored by Beijing Nova Program 20250484944
6 · The paper itself

Abstract

STING agonists (e.g., cGAMP), which function as immunotherapeutic agents activating the stimulator of interferon genes (STING) pathway, hold promise for treating pediatric solid tumors including neuroblastoma. However, their clinical translation is hindered by limitations including burst release, short half-life, poor targeting, and low intracellular delivery efficiency. In this study, we engineered a peptide self-assembled nanofiber (NFSA) based on the specific interaction mechanism between STING protein and cGAMP. By hydrophobically modifying the cGAMP-binding amino acid sequences on STING, two amphiphilic peptides, MP1 and MP2, were obtained, which self-assembled into nanofibers to efficiently encapsulate cGAMP. The NFSA showed excellent biocompatibility and low toxicity both in vitro and in vivo. It enabled pH-responsive cGAMP release, promoted cellular uptake, enhanced the endoplasmic reticulum (ER) localization, and activated the STING pathway. NFSA also promoted dendritic cell maturation and shifted tumor-associated macrophages to the anti-tumor M1 type. In vivo, NFSA reduced neuroblastoma growth, increased CD8

Indexed as

immunotherapyneuroblastomapeptide self‐assembled delivery systempH‐responsive releaseSTING agonists

Identifiers

PMID42801624
PMCPMC13616383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.